Trial Search Results
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Targeted Therapy Technologies, LLC
Stanford Investigator(s):
Intervention(s):
- Drug: Episcleral Dexamethasone
Phase:
Phase 1
Eligibility
Inclusion Criteria:
- Age >= 18 years;
- Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
equivalent 20/32 to 20/320);
- Ophthalmoscopic evidence of center-involved macular edema, within the central subfield
(CSF);
- Inflammatory disorders of the sclera, choroid, retina or vitreous
Exclusion Criteria:
- Inability to understand informed consent, cooperate with testing or return to follow
up visits;
- Pregnant or lactating women;
- Co-existent ocular disorder of the cornea, lens or media that will interfere with
assessment of safety or efficacy.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amy Dennis, RN
650-497-7935
Recruiting